Champaloux Steven W, Tepper Naomi K, Monsour Michael, Curtis Kathryn M, Whiteman Maura K, Marchbanks Polly A, Jamieson Denise J
Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA.
Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA.
Am J Obstet Gynecol. 2017 May;216(5):489.e1-489.e7. doi: 10.1016/j.ajog.2016.12.019. Epub 2016 Dec 26.
Migraine with aura and combined hormonal contraceptives are independently associated with an increased risk of ischemic stroke. However, little is known about whether there are any joint effects of migraine and hormonal contraceptives on risk of stroke.
We sought to estimate the incidence of stroke in women of reproductive age and examine the association among combined hormonal contraceptive use, migraine type (with or without aura), and ischemic stroke.
This study used a nationwide health care claims database and employed a nested case-control study design. Females ages 15-49 years with first-ever stroke during 2006 through 2012 were identified using the International Classification of Diseases, Ninth Revision, Clinical Modification inpatient services diagnosis codes. Four controls were matched to each case based on age. Migraine headache with and without aura was identified using inpatient or outpatient diagnosis codes. Current combined hormonal contraceptive use was identified using the National Drug Code from the pharmacy database. Conditional logistic regression was used to estimate adjusted odds ratios and 95% confidence intervals of ischemic stroke by migraine type and combined hormonal contraceptive use.
From 2006 through 2012, there were 25,887 ischemic strokes among females ages 15-49 years, for a cumulative incidence of 11 strokes/100,000 females. Compared to those with neither migraine nor combined hormonal contraceptive use, the odds ratio of ischemic stroke was highest among those with migraine with aura using combined hormonal contraceptives (odds ratio, 6.1; 95% confidence interval, 3.1-12.1); odds ratios were also elevated for migraine with aura without combined hormonal contraceptive use (odds ratio, 2.7; 95% confidence interval, 1.9-3.7), migraine without aura and combined hormonal contraceptive use (odds ratio, 1.8; 95% confidence interval, 1.1-2.9), and migraine without aura without combined hormonal contraceptive use (odds ratio, 2.2; 95% confidence interval, 1.9-2.7).
The joint effect of combined hormonal contraceptives and migraine with aura was associated with a 6-fold increased risk of ischemic stroke compared with neither risk factor. Use of combined hormonal contraceptives did not substantially further increase risk of ischemic stroke among women with migraine without aura. Determining migraine type is critical in assessing safety of combined hormonal contraceptives among women with migraine.
伴有先兆的偏头痛和复方激素避孕药均与缺血性中风风险增加独立相关。然而,对于偏头痛和激素避孕药对中风风险是否存在任何联合效应,人们知之甚少。
我们试图估计育龄女性中风的发病率,并研究复方激素避孕药的使用、偏头痛类型(有无先兆)与缺血性中风之间的关联。
本研究使用了全国性的医疗保健索赔数据库,并采用了巢式病例对照研究设计。通过《国际疾病分类第九版临床修订本》的住院服务诊断代码,确定了2006年至2012年期间首次中风的15至49岁女性。根据年龄为每个病例匹配4名对照。通过住院或门诊诊断代码确定有无先兆的偏头痛。使用药房数据库中的国家药品代码确定当前复方激素避孕药的使用情况。采用条件逻辑回归来估计按偏头痛类型和复方激素避孕药使用情况调整后的缺血性中风比值比及95%置信区间。
2006年至2012年期间,15至49岁女性中有25,887例缺血性中风,累积发病率为每10万名女性中有11例中风。与既无偏头痛也未使用复方激素避孕药的女性相比,使用复方激素避孕药的伴有先兆偏头痛女性的缺血性中风比值比最高(比值比为6.1;95%置信区间为3.1 - 12.1);未使用复方激素避孕药的伴有先兆偏头痛女性的比值比也升高(比值比为2.7;95%置信区间为1.9 - 3.7),无先兆偏头痛且使用复方激素避孕药的女性(比值比为1.8;95%置信区间为1.1 - 2.9),以及无先兆偏头痛且未使用复方激素避孕药的女性(比值比为2.2;95%置信区间为1.9 - 2.7)。
与无任何风险因素相比,复方激素避孕药与伴有先兆偏头痛的联合效应使缺血性中风风险增加了6倍。对于无先兆偏头痛女性,使用复方激素避孕药并未实质性进一步增加缺血性中风风险。确定偏头痛类型对于评估偏头痛女性使用复方激素避孕药的安全性至关重要。